Charles Schwab
SBBP

Charles Schwab’s Strongbridge Biopharma plc. SBBP Stock Holding History

Charles Schwab’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,233
Closed -$87K – 3577
2021
Q2 		$87K Sell
29,233
-74,519
-72% -$197K ﹤0.01% 3306
2021
Q1 		$287K Sell
103,752
-14,991
-13% -$45.2K ﹤0.01% 3256
2020
Q4 		$289K Buy
118,743
+16,496
+16% +$39.7K ﹤0.01% 3172
2020
Q3 		$215K Hold
102,247
– – ﹤0.01% 3157
2020
Q2 		$387K Buy
102,247
+27,016
+36% +$81K ﹤0.01% 2935
2020
Q1 		$143K Hold
75,231
– – ﹤0.01% 3068
2019
Q4 		$158K Hold
75,231
– – ﹤0.01% 3065
2019
Q3 		$180K Hold
75,231
– – ﹤0.01% 3053
2019
Q2 		$236K Buy
+75,231
New +$276K ﹤0.01% 3065
2018
Q2 		– Sell
-58,000
Closed -$514K – 3173
2018
Q1 		$514K Buy
58,000
+11,600
+25% +$86.8K ﹤0.01% 2720
2017
Q4 		$337K Hold
46,400
– – ﹤0.01% 2840
2017
Q3 		$321K Hold
46,400
– – ﹤0.01% 2849
2017
Q2 		$332K Buy
+46,400
New +$214K ﹤0.01% 2827

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Charles Schwab's SBBP Position: Q3 2021 in Review

Charles Schwab sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2021, closing a stake of 29,233 shares — an estimated $87K sold.

Charles Schwab first reported a position in SBBP in Q2 2017 and held it in 13 quarters. The position peaked at $514K in Q1 2018. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2021.

  • Charles Schwab reported no remaining Strongbridge Biopharma plc. position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 29,233 Strongbridge Biopharma plc. shares in Q3 2021, an estimated $87K.
  • Charles Schwab first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 13 quarters.
  • Charles Schwab's Strongbridge Biopharma plc. position peaked at $514K in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.